Hims & Hers: Bargain EBITDA Multiples As GLP-1 Drama Passes

Hims & Hers has fallen nearly 40% year to date and about two-thirds from its peak, leaving the stock at what the article describes as a compressed valuation. The market is pricing in slight adjusted EBITDA margin contraction in FY26 as the company expands into Europe and Japan, but the $1.15 billion Eucalyptus acquisition, set to close in mid-2026, should accelerate its international rollout and support overseas profitability.

Analysis

The selloff looks less like a fundamental deterioration than a regime change in how the market is valuing growth: HIMS is being priced as if international expansion is a near-term drag with limited option value, when in reality the overseas buildout creates a second growth vector that could re-rate the multiple once execution risk is de-risked. The key second-order effect is that management can trade a modest margin dip for a materially larger addressable market, and that usually matters more in platform businesses than a single-year EBITDA inflection.

The consensus appears to be underestimating how much of the current compression is sentiment-driven. When a high-multiple consumer-health platform derates this sharply, marginal sellers often dominate until a concrete catalyst resets expectations; that means the stock can remain weak for weeks even if the medium-term thesis is intact. But once the market starts to view the Eucalyptus deal as an execution bridge rather than a dilution event, the path to multiple expansion could be fast because positioning is likely still damaged.

Competitive dynamics matter: a successful international push would pressure smaller telehealth and digital pharmacy peers that lack HIMS’ balance-sheet flexibility and brand reach, while putting incumbents in pharma-distribution and brick-and-mortar health services on the defensive. The flip side is integration risk: if overseas growth comes with hidden CAC inflation, regulatory friction, or slower monetization than modeled, the market will punish the stock again because it has already lowered the bar. This sets up a binary setup over a 6-18 month horizon, with the near-term tape likely driven more by guidance credibility than by absolute growth rates.

The contrarian read is that the market may be over-discounting a temporary margin give-up and underpricing the optionality of a replicable international playbook. The move is likely overdone if management can show a clear path to overseas cohort economics within 2-3 quarters post-close; it is underdone if the acquisition turns out to be merely a capital allocation story without operating leverage. The critical question is not whether FY26 margins compress, but whether that compression is buying a durable step-up in terminal growth.

Key Decisions for Investors

• Initiate a starter long in HIMS now, then add on any post-guidance weakness over the next 2-6 weeks; expect asymmetric upside if management can preserve investor confidence into the Eucalyptus close, with a 20-30% rerating potential over 6-12 months versus high-teens downside if execution slips.
• Use a defined-risk call spread in HIMS for 6-9 months out to express the re-rating thesis; this fits a thesis where the stock can grind lower near term but gap higher on evidence that international expansion is additive rather than dilutive.
• Pair long HIMS against a basket of smaller telehealth/digital health names that lack scale and international optionality over the next 3-6 months; the relative-value trade benefits if investors reward platforms with balance-sheet flexibility and punish weaker operators exposed to CAC inflation.
• Avoid chasing on the first bounce; wait for either a volume-backed reversal or an update that clarifies post-close margin trajectory, because the stock likely needs a catalyst to unwind sentiment-driven positioning.
• If HIMS rallies back toward pre-selloff valuation before the acquisition closes, trim 25-50% and keep only a core position into the integration window, since the biggest upside should come from proof points rather than headline deal optionality.